Geriatric assessment predicts survival and competingmortality in elderly patients with early colorectal cancer: Can it help in adjuvant therapy decision-making?

Oncologist

Volumn 22, Issue 8, 2017, Pages 934-943

  Antonio, Maite ^a   Saldaña, Juana ^a   Carmona Bayonas, Alberto ^b   Navarro, Valentín ^c   Tebé, Cristian ^d   Nadal, Marga ^c   Formiga, Francesc ^e   Salazar, Ramon ^a   Borràs, Josep Maria ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Adjuvant therapy; Colorectal cancer; Competing risk model; Comprehensive geriatric assessment; Decision making; Elderly

Indexed keywords

CAPECITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; COGNITION; COGNITIVE DEFECT; COLORECTAL CANCER; DECISION MAKING; DELIRIUM; FALLING; FECES INCONTINENCE; FEMALE; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; POLYPHARMACY; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DECISION MAKING; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; PROGNOSIS; RISK FACTORS;

EID: 85027307763     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0462     Document Type: Article

References (42)

1. Shih YC, Hurria A. Preparing for an epidemic: Cancer care in an aging population. Am Soc Clin Oncol Educ Book 2014: 133-137.
2. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64: 9-29.
3. National Cancer Institute: Surveillance, Epidemiology, and End Results Program: SEER Fact Sheets-Colon and rectum Cancer. Available at https://seer. cancer.gov/statfacts/html/colorect.html. Accessed April 4, 2017.
4. Brenner H, Bouvier AM, Foschi R et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: The EUROCARE study. Int J Cancer 2012;131: 1649-1658.
5. Holleczek B, Rossi S, Domenic A et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999-2007-Results from the EUROCARE-5 study. Eur J Cancer 2015 [Epub ahead of print].
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon cancer.Version 2.2015. 2015.
7. van Erning FN, Janssen-HeijnenML, Creemers GJ et al. Deciding on adjuvant chemotherapy for elderly stage III colon cancer patients: A qualitative insight into the perspectives of surgeons andmedical oncologists. J Geriatr Oncol 2015;6: 219-224.
8. Hung A, Mullins CD. Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: A systematic review. The Oncologist 2013;18: 54-63.
9. Aparicio T, Navazesh A, Boutron I et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol 2009;71: 249-257.
10. Serra-Rexach JA, Jimenez AB, García-Alhambra MA et al. Differences in the therapeutic approach to colorectal cancer in young and elderly patients. The Oncologist 2012;17: 1277-1285.
11. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology study. J Clin Oncol 2002;20: 494-502.
12. Wildiers H, Heeren P, PutsMet al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014;32: 2595-2603.
13. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25: 1824-1831.
14. Puts MT, Hardt J, Monette J et al. Use of geriatric assessment for older adults in the oncology setting: A systematic review. J Natl Cancer Inst 2012; 104: 1133-1163.
15. Kenis C, Bron D, Libert Y et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: Results of a prospective multicentric study. Ann Oncol 2013;24: 1306-1312.
16. ExtermannM, Boler I, Reich RR et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012;118: 3377-3386.
17. Hurria A, Togawa K, Mohile SG et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 2011;29: 3457-3465.
18. Berry SD, Ngo L, Samelson EJ et al. Competing risk of death: An important consideration in studies of older adults. J Am Geriatr Soc 2010;58: 783-787.
19. Labianca R, Nordlinger B, Beretta GD et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(suppl 6): vi64-vi72.
20. Mahoney FI, Barthel DW. Functional evaluation: The Barthel index. Md State Med J 1965;14: 61-65.
21. Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969;9: 179-186.
22. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975;23: 433-441.
23. D’Ath P, Katona P, Mullan E et al. Screening, detection and management of depression in elderly primary care attenders. I: The acceptability and performance of the 15 item Geriatric Depression Scale (GDS15) and the development of short versions. FamPract 1994;11: 260-266.
24. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40: 373-383.
25. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J AmGeriatr Soc 1968;16: 622-626.
26. Balducci L, Extermann M. Management of cancer in the older person: A practical approach. The Oncologist 2000;5: 224-237.
27. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94: 496-509.
28. Andersen PK, Geskus RB, de Witte T et al. Competing risks in epidemiology: Possibilities and pitfalls. Int J Epidemiol 2012;41: 861-870.
29. Team RC. R: A language and environment for statistical computing. Vienna ARF for SC 2012. Available at http://cran r-project org. Accessed April 7, 2017.
30. Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345: 1091-1097.
31. Papamichael D, Audisio RA, Glimelius B et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 2015;26: 463-476.
32. Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol 2014;25: 307-315.
33. Hamaker ME, Schiphorst AH, ten Bokkel Huinink D et al. The effect of a geriatric evaluation on treatment decisions for older cancer patients-A systematic review. Acta Oncol 2014;53: 289-296.
34. Ommundsen N, Wyller TB, Nesbakken A et al. Frailty is an independent predictor of survival in older patients with colorectal cancer. The Oncologist 2014;19: 1268-1275.
35. Böckelman C, Engelmann BE, Kaprio T et al. Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta Oncol 2015;54: 5-16.
36. Sargent DJ, Wieand HS, Haller DG et al. Disease- free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23: 8664-8670.
37. Sun W, Jiang YZ, Liu YR et al. Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer. Oncotarget 2016;7: 20496-20506.
38. Raldow AC, Zhang D, Chen MH et al. Risk group and death from prostate cancer: Implications for active surveillance in men with favorable intermediate-risk prostate cancer. JAMA Oncol 2015; 1: 334-340.
39. Weng SF, Chiu YH, Jan RL et al.Death doesmatter-Cancer risk in patients with end-stage renal disease. Medicine (Baltimore) 2016;95: e2512.
40. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol 2013;31: 468-474.
41. Carmona R, Zakeri K, Green G et al. Improved method to stratify elderly patients with cancer at risk for competing events. J Clin Oncol 2016;34: 1270-1277.
42. Hurria A, Wildes T, Blair SL et al. Senior adult oncology, Version 2.2014: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2014;12: 82-126.